Back to top

Analyst Blog

On Sep 5, Teleflex Incorporated (TFX - Snapshot Report) broadcasted a live lung isolation surgery to demonstrate the efficacy of its latest Rusch EZ-Blocker Endobronchial Blocker. This device was developed as a superior alternative to traditional double-lumen endobronchial tubes and single balloon bronchial blockers.

According to an Anesthesiology journal, bronchial blockers can overcome many of the drawbacks of double-lumen endobronchial tubes, like the increased risk for airway trauma, when compared to single-lumen endotracheal tubes. Yet another medical journal had highlighted the inefficiency of the single-cuff endobronchial blockers, explaining why such devices receive limited acceptance among anesthesiologists.

The EZ-Blocker Endobronchial Blocker has a unique Y-shaped distal, matching the bifurcation of the trachea, which allows for the intuitive placement of the balloons in the right or left bronchus. Moreover, it can be securely placed at the carina without any navigation assistance, thereby enhancing clinical efficiency.

The broadcast was hosted from an operating room at Radbound University Nijmegen Medical Centre, The Netherlands, to educate clinicians across the globe regarding the benefits of the new EZ-Blocker Endobronchial Blocker. This marketing initiative by Teleflex should help boost the product’s popularity in the international markets, going forward.

TFX is a global leader in supply of medical devices used in critical care and surgery. The company focuses on profitable and consistent growth and expects its sales growth to surpass market growth in the long run. It also plans to gain market share in key product areas.

However, the company operates in a highly competitive medical devices industry and stringent regulatory environment. The demand for its products is susceptible to healthcare reimbursement systems in the domestic as well as the international market.

TFX has a Zacks Rank #3 (Hold). While we remain on the sidelines regarding this company, other medical instruments stocks that are worth considering include Luminex (LMNX - Analyst Report), Given Imaging and Echo Therapeutics (ECTE - Snapshot Report). All these stocks carry a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%